W18
AI-powered Drug DiscoveryDeep Learning
Active

Macromoltek

Computational antibody design

Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.

Macromoltek
Founded2010
Team Size14
LocationAustin, TX

Monica Berrondo, CEO

Monica Berrondo, Ph.D., is an entrepreneur, scientist, and software engineer. Her expertise lies in antibody structure-prediction and analysis, protein functional analysis, protein mutational analysis, and computational approaches to complex scientific problems.

Monica Berrondo
Macromoltek

Susana Kaufmann, CTO

Susana Kaufmann
Macromoltek